New drug could offer lasting cure for certain high blood pressure cases

A study led by Queen Mary University of London suggests the drug baxdrostat may kill hormone-producing cells, potentially providing a permanent cure for some patients.

A study led by Queen Mary University of London has found that a new treatment could offer a lasting cure for some people with a common hormonal cause of high blood pressure, even after they stop taking medication. The drug, called baxdrostat, is an aldosterone synthase inhibitor that suppresses the blood pressure-raising hormone.

In 5 to 10% of cases, hypertension is caused by small benign tumours on the adrenal glands that overproduce a hormone called aldosterone. This excess hormone raises blood pressure by signalling the kidneys to retain salt. While surgery to remove the affected adrenal gland is the standard treatment, it is not always a complete cure.

In a small study following 14 patients, blood pressure improved dramatically during a three-month trial. The patients continued taking the daily pills for six to 12 months and then stopped. When doctors checked the patients up to two years later, their blood pressure remained lower, and just under a quarter of the patients had come off all treatment and had completely normal blood pressure.

Professor Morris Brown, a hypertension specialist at Queen Mary University of London, said the drug may cure primary aldosteronism because it may cause a surge in reactive oxygen species that selectively destroy the cells that overproduce the hormone. He noted that those oxygen radicals kill the cells and they disappear.

Mason Freeman, a professor of medicine at Harvard Medical School, said the follow-up study generated extraordinary and unexpected findings. The sustained remission offers the possibility that many patients with adrenal gland tumours may be treated with a once-a-day pill for a limited period and obtain benefits similar to major adrenal surgery.

Baxdrostat was approved in the US earlier this year for patients with hypertension not controlled by existing drugs. It is being assessed by the National Institute for Health and Care Excellence, which could make the drug available through the NHS next year.

Key facts

  • Just under a quarter of patients in the study came off all treatment and had completely normal blood pressure.
  • Baxdrostat was approved in the US earlier this year for patients with hypertension not controlled by existing drugs.
  • The drug may work by causing reactive oxygen species to destroy cells that overproduce aldosterone.

Three perspectives

Neutral

The study suggests that baxdrostat could provide a lasting effect for some patients with hormone-related hypertension.

Positive

The findings offer the exciting possibility that patients could obtain benefits similar to major surgery through a limited course of a daily pill.

Negative

A larger study is still required to really prove these findings.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

All sections

Edition